Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12. - Wikidata - wikimedia - TriplyDB

Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12.

Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12.

http://www.wikidata.org/entity/Q40511274

about

Dendritic cell-based cancer immunotherapy for colorectal cancer Immunologic monitoring of cellular responses by dendritic/tumor cell fusion vaccines.Current immunotherapeutic approaches in pancreatic cancer.Gene Expression Profile of Dendritic Cell-Tumor Cell Hybrids Determined by Microarrays and Its Implications for Cancer Immunotherapy Trial watch: Dendritic cell-based interventions for cancer therapy Cell fusion: from hybridoma to dendritic cell-based vaccine.Cancer immunotherapy by fusions of dendritic cells and tumor cells.Regulation of tumor immunity by tumor/dendritic cell fusions Recent advances and developments in the antitumor effect of the HVJ envelope vector on malignant melanoma: from the bench to clinical application.The impact of dendritic cell-tumor fusion cells on cancer vaccines - past progress and future strategies.Superior anti-tumor protection and therapeutic efficacy of vaccination with dendritic cell/tumor cell fusion hybrids for murine Lewis lung carcinoma.In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells Preparation of a heat-shock protein 70-based vaccine from DC-tumor fusion cells.A Novel Heat Shock Protein 70-based Vaccine Prepared from DC-Tumor Fusion Cells.

P2860

Q26751339-C6544478-BEC2-400F-BDD5-D7E783610E28 Q34898366-64E06329-B3D5-4BCD-80FA-BDC0874DB4A7 Q35212837-653CB660-5816-4ABC-A56E-B4FD00D2586C Q36269842-7A2B2B46-9A02-4296-A7F1-1CF83FB914F9 Q36388529-03EE14A6-C520-49BE-9FEF-4BB2A3E06B73 Q37259630-DC969573-0B2D-4D7A-8BB2-CDFA3AFB95C4 Q37773276-4334F459-8FA8-4724-959E-B1B6273009F5 Q37806963-6A76D5D0-29CC-46D3-AEE3-3F701C20C3B0 Q38155377-C1AF290F-7E86-44F9-B41C-3F3EA393DCDC Q38617733-B4A09B1C-5687-4795-80E3-BC2C9EAD7479 Q39066916-95D2C058-045A-4636-80D8-83ABA83D3383 Q39939752-61E8C08E-0E50-4B11-8E01-5690F9497EF3 Q42726581-74E430A3-C788-4832-B3B7-171C8B3B51D3 Q47362481-5BEA8B09-37AC-4052-A78F-0BA198AECCA2

P2860

Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12.

http://www.wikidata.org/entity/Q40511274

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12.

@en

type

label

Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12.

@en

prefLabel

Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12.

@en

P1433

Q40511274-2E732D78-2433-47E5-B915-66A5311456F5

P1476

Q40511274-2AC9ACE4-6864-4682-AB53-D8ED35647DD2

P2093

Q40511274-00E337BB-B17E-4F70-98F9-62F12F4E895F

Q40511274-2EBFEE2C-67AF-4D44-BCAE-8E5DCD8784B1

Q40511274-40F2FF3D-70B3-4EE1-86A5-A5DF6D758777

Q40511274-435A1EC7-D5F8-4731-8995-ADB0217B1FD3

Q40511274-4366359C-DF13-481B-9330-DD6D6D3C0593

Q40511274-87A6012F-0046-40DB-86A9-AC0FD6730544

Q40511274-8FBE2D49-AABA-40B0-9B53-17951C22179B

Q40511274-C060133A-3646-422D-B0B8-493F2A646C73

Q40511274-C6825838-D977-40D1-A9A3-DF435BBACF4B

Q40511274-DA9B380D-257F-41A9-B53C-BE19704B36EA

P2860

Q40511274-1896E508-2019-4ACC-9424-FBD44D9EB752

Q40511274-2A763ABA-63C5-4095-B90F-A7D198CB0989

Q40511274-597BA81A-24D0-460E-91F5-A0710560B16F

Q40511274-5DC6B7E6-AB73-40B3-936F-52530CA0422A

Q40511274-5DD96DAE-DFE6-47F8-BE62-FD9F162EB271

Q40511274-60ADD2A8-5838-4DAC-A872-E5E63E2646E1

Q40511274-60B962A6-1996-4EB9-8556-A5771D53260C

Q40511274-71D41CA3-267C-4F60-B652-79778BA5E367

Q40511274-78949534-B2EE-4994-9A9A-6A568C7F8CA3

Q40511274-90AD0A47-5AC2-4A42-9196-173788888FA5

P304

Q40511274-39BA593B-6622-44CE-948F-48CCF1FDC1CD

P31

Q40511274-6DFE33C6-49FB-4194-B1B4-1266A9D2E960

P356

Q40511274-2129D6F9-829B-437B-98BD-5DD78B5DFF7A

P433

Q40511274-95B50820-4E42-4FE7-9136-6E63D267D8D6

P478

Q40511274-EEAD02CA-7784-49BE-8E73-3DBF3DDD4BF6

P577

Q40511274-69AED0FC-EC0A-4DBA-93AE-9376D4BA1FB3

P698

Q40511274-A61F58D0-9FF7-4FF8-B5A4-96FBA662C480

P356

J.1365-2362.2005.01494.X

P1433

European Journal of Clinical Investigation

P1476

Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12.

@en

P2093

Hara E

http://www.w3.org/2001/XMLSchema#string

Homma S

http://www.w3.org/2001/XMLSchema#string

Ishiji N

http://www.w3.org/2001/XMLSchema#string

Kikuchi T

http://www.w3.org/2001/XMLSchema#string

Kufe D

http://www.w3.org/2001/XMLSchema#string

Ochiai K

http://www.w3.org/2001/XMLSchema#string

Ohno T

http://www.w3.org/2001/XMLSchema#string

Ryan JL

http://www.w3.org/2001/XMLSchema#string

Sagawa Y

http://www.w3.org/2001/XMLSchema#string

Saotome H

http://www.w3.org/2001/XMLSchema#string

P2860

Dendritic cells and the control of immunity

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome.

Dendritic cell immunotherapy: mapping the way.

A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes.

Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity

A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma.

Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.

Inhibition of spontaneous development of liver tumors by inoculation with dendritic cells loaded with hepatocellular carcinoma cells in C3H/HeNCRJ mice.

Hybrid cell vaccination in metastatic melanoma: clinical and immunologic results of a phase I/II study.

P304

279-286

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2362.2005.01494.X

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P577

2005-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15816998

http://www.w3.org/2001/XMLSchema#string